Clinical Trial Update: Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated Myfortic (mycophenolate mofetil) in combination with tacrolimus and thymoglobulin for early corticosteroid withdrawal in end-stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• MYFORTIC (MYCOPHENOLIC ACID)
• Prograf (Tacrolimus)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University of Cincinnati | Conditions: End Stage Renal Disease (ESRD) | Phase 4 | Status: COMPLETED | Results posted: 2012-05-08